Could Psycho-bio-social Context and Personality be a Predictive Factor of Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease Patients? - PERSO-PERF Study

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Since our previous study has shown that some personality dimensions were associated with Quality of Life (QoL) amelioration after Deep Brain Stimulation (DBS) in Parkinson's disease (PD), the investigators aim to evaluate the impact of personality dimensions on therapeutic response after another second-line treatment: the continuous subcutaneous apomorphine infusion (CSAI). Moreover, the investigators would like to evaluate the potential evolution of personality dimensions through CSAI. The investigators also aim to evaluate other bio-psycho-social factors (representations of the disease, ways of copying and social support) influence on QoL amelioration after DBS.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Parkinson's disease patients as defined by the United Kingdom Parkinson's disease Brain Bank (UKPDSBB) criteria and aged from 40 to 75 years old (included)

• Patients with motor fluctuations and/or invalidating dyskinesia and awaiting CSAI establishment in the context of their usual care for PD

• Patients affiliated to a social security system

Locations
Other Locations
France
Chu de Lyon
RECRUITING
Bron
Hopital Gabriel Montpied
RECRUITING
Clermont-ferrand
Chu de Grenoble
RECRUITING
Grenoble
Chu Limoges
RECRUITING
Limoges
Chu de Nancy
RECRUITING
Nancy
Chu de Nice
RECRUITING
Nice
Chu de Poitiers
RECRUITING
Poitiers
Chu de Rennes
RECRUITING
Rennes
Chu de Rouen
RECRUITING
Rouen
Chu de Toulouse
RECRUITING
Toulouse
Contact Information
Primary
CHRISTINE BREFEL COURBON
christine.brefel-courbon@univ-tlse3.fr
(0)5 61 77 25 35
Backup
ESTELLE HARROCH
harroch.e@chu-toulouse.fr
Time Frame
Start Date: 2024-02-15
Estimated Completion Date: 2026-04-01
Participants
Target number of participants: 70
Sponsors
Collaborators: NHC SAS, France, EVER Pharma France SAS, ETPARK Association, Toulouse, France, Orkyn', ELIVIE France
Leads: University Hospital, Toulouse

This content was sourced from clinicaltrials.gov

Similar Clinical Trials